Published in Vaccine Weekly, February 15th, 1999
Recombinant adeno-associated virus (rAAV) is already known by gene-therapy researchers, who are exploring the use of its unique properties as a DNA delivery vehicle. Now vaccinologists hope to take advantage of AAV's unique properties in the quest for today's Holy Grail: an HIV vaccine.
To date, no experimental AIDS vaccine has succeeded in the induction of long-lasting HIV specific humoral responses without repeated boosting. But a preliminary experiment with macaque monkeys has shown that a single inoculation with rAAV carrying...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly